Women's Testosterone: Dosing, Monitoring & Endocrine Effects

Women's Testosterone Therapy: Clinical Mechanics and Monitoring

Women's testosterone deficiency is historically underdiagnosed and undertreated. Unlike men, female testosterone operates across a narrower physiologic window—but that window is precisely where therapeutic benefit concentrates. The trend toward women's testosterone replacement reflects not a fad, but accumulated evidence that many women experience symptomatic hypogonadism that responds predictably to carefully titrated replacement.

Physiologic vs. Supraphysiologic Dosing

The critical distinction: physiologic replacement aims to restore normal female ranges (30–80 ng/dL total testosterone, 5–15 pg/mL free testosterone), whereas supraphysiologic dosing chases male-range levels. Women's testosterone therapy should remain physiologic.

Typical starting protocols use microdosing:

• Transdermal cream: 0.5–2 mg daily
• Pellets: 25–75 mg implanted every 3–6 months
• Oral methyltestosterone: 0.5–2.5 mg daily (rarely used; higher hepatic burden)

Doses are titrated upward by 0.5–1 mg increments based on symptom response and lab confirmation. This is not a "more is better" hormone. The ceiling of benefit in women drops steeply beyond physiologic range; excess testosterone drives virilization, lipid dysfunction, and polycystic ovary exacerbation.

Endocrine Axis Interactions

Testosterone replacement in women triggers cascading effects across multiple axes:

The GH/IGF-1 axis: Testosterone potentiates growth hormone secretion and amplifies IGF-1 production. This is mechanistically relevant. Women on testosterone often experience improved body composition, strength gains, and metabolic efficiency partly through this potentiation. However, this requires baseline IGF-1 measurement and periodic re-testing (every 6–12 months) to ensure levels remain within optimal range (100–150 ng/mL is the target for healthy aging; reference ranges often extend to 300+ and miss the nuance).

Estrogen conversion: Testosterone aromatizes to estradiol. In women, this is beneficial—estradiol supports bone, cardiovascular, and cognitive health. However, excess aromatization (seen at supraphysiologic doses or in women with high body fat) can cause bloating, mood changes, and breast tenderness. Baseline estradiol measurement (goal: 40–60 pg/mL) and repeat testing at 6–8 weeks post-initiation is standard.

Thyroid and cortisol: Testosterone modulates thyroid receptor sensitivity and can improve insulin sensitivity, lowering cortisol in chronically stressed women. These are secondary benefits, but worth tracking via TSH, free T3, free T4, and 24-hour cortisol or morning cortisol + ACTH.

Laboratory Protocol for Women on Testosterone

Baseline (before starting):

• Total testosterone, free testosterone, bioavailable testosterone
• Estradiol (ultrasensitive assay)
• IGF-1
• Complete lipid panel (testosterone can lower HDL, raise LDL in some women)
• Liver function tests (AST, ALT)
• TSH, free T3, free T4
• Hematocrit/hemoglobin (testosterone stimulates RBC production; hematocrit should not exceed 48%)
• DHEA-S, cortisol

6–8 weeks post-initiation:

• Total testosterone, free testosterone
• Estradiol
• Hematocrit

Every 6–12 months thereafter:

• Total testosterone, free testosterone, estradiol
• IGF-1
• Lipid panel
• Liver function tests
• Hematocrit

Optimal vs. Reference Ranges

This distinction is critical. Reference ranges are population averages; optimal ranges are therapeutic targets.

Testosterone:

• Reference range (women): 15–70 ng/dL
• Optimal therapeutic range: 40–80 ng/dL (physiologic replacement target)
• Above 80 ng/dL: risk of virilization increases

Estradiol:

• Reference range: 10–60 pg/mL
• Optimal during testosterone replacement: 40–60 pg/mL (supports bone, cognition, cardiovascular health)
• Below 30 pg/mL: increased bone loss, vaginal dryness, mood changes
• Above 80 pg/mL: bloating, breast tenderness, increased clot risk

IGF-1:

• Reference range: often 100–300 ng/mL (varies by age)
• Optimal for longevity and strength: 100–150 ng/mL
• Above 200 ng/mL in women: increased cancer risk signals and acanthosis nigricans in susceptible individuals

Hematocrit:

• Reference range: 36–46%
• Maximum safe on testosterone: 48–50% (above this, stroke and clot risk rise)

Synergistic Supplementation

Women on testosterone benefit from stacking:

Magnesium glycinate (300–400 mg daily): Reduces cortisol, supports muscle recovery, aids sleep (testosterone increases protein synthesis demand).

Zinc (15–25 mg daily): Cofactor for testosterone production and metabolism; supports immune function (testosterone can suppress some immune markers).

Vitamin D3 + K2: Testosterone increases bone turnover. D3 (2000–4000 IU daily) and K2 (MK-7, 90–180 mcg daily) maintain bone mineral density.

NAC (1200–1800 mg daily): Supports liver health during hormone metabolism; antioxidant protection.

Omega-3 (2–3g EPA+DHA daily): Mitigates testosterone-driven lipid shifts; supports cardiovascular health.

Safety Red Flags

Monitor for virilization (deepening voice, clitoral enlargement, male-pattern hair growth). These are dose-dependent and often reversible if caught early, but require dose reduction. Hematocrit above 50% mandates dose reduction or phlebotomy. Any LDL rise above 130 mg/dL requires dietary or pharmacologic intervention.

Bottom Line

Women's testosterone therapy, when dosed physiologically and monitored rigorously, restores function without crossing into supraphysiologic territory. Success requires baseline labs, 6–8 week reassessment, annual monitoring, and titration discipline. The endocrine axis responds predictably; the key is respecting dose ceilings and reading the biomarker language your body is speaking.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.